c-Src/histone deacetylase 3 interaction is crucial for hepatocyte growth factor-dependent decrease of CXCR4 expression in highly invasive breast tumor cells

Molecular Cancer Research

Volumn 5, Issue 8, 2007, Pages 833-845

  Matteucci, Emanuela ^a   Ridolfi, Elisa ^a   Maroni, Paola ^a   Bendinelli, Paola ^a   Desiderio, Maria Alfonsina ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HISTONE DEACETYLASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTYROSINE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR; TRANSCRIPTION FACTOR ETS 1;

ARTICLE; BREAST TUMOR; CELL NUCLEUS; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; TUMOR CELL;

BLOTTING, WESTERN; BREAST NEOPLASMS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HEPATOCYTE GROWTH FACTOR; HISTONE DEACETYLASES; HUMANS; IMMUNOPRECIPITATION; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTORS, CXCR4; TRANS-ACTIVATION (GENETICS);

EID: 34548104593     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0054     Document Type: Article

References (52)

1. Boccaccio C, Comoglio PM. Invasive growth: a Met-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-45.
2. Trusolino L, Cavassa S, Angelini P, et al. HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J 2000;14:1629-40.
3. Matteucci E, Ridolfi E, Desiderio MA. Hepatocyte growth factor differently influences Met - Ecadherin phosphorylation and downstream signalling pathway in two models of breast cells. Cell Mol Life Sci 2006;63:2016-26.
4. Ostapkowicz A, Inai K, Smith L, Kreda S, Spychala J. Lipid rafts remodelling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor. Mol Cancer Ther 2006;5:238-45.
5. Wojcik EJ, Sharifpoor S, Miller NA, et al. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 2006;25:2773-84.
6. Sheen-Chen SM, Liu YW, Eng HL, Chou F-F. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:715-7.
7. Elliott BE, Hung WL, Boag AH, Tuck AB. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol 2002;80:91-102.
8. Khoury H, Dankort DL, Sadekova S, Naujokas MA, Muller W, Park M. Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene 2001;20:788-99.
9. Lengyel E, Prechtel D, Resau JH, et al. c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2004;113:678-82.
10. Tacchini L, Matteucci E, De Ponti C, Desiderio MA. Hepatocyte growth factor signalling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. Exp Cell Res 2003;290:391-401.
11. Matteucci E, Locati M, Desiderio MA. Hepatocyte growth factor enhances CXCR4 expression favouring breast cancer cell invasiveness. Exp Cell Res 2005;310:176-85.
12. Balkwill F. Chemokine biology in cancer. Semin Immunol 2003;15:49-55.
13. Balkwill F. Cancer and chemokine network. Nat Rev Cancer 2004;4:540-50.
14. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell 2004;6:209-14.
15. Bertotti A, Comoglio PM. Tyrosine kinase signal specificity. Trends Biochem Sci 2003;28:527-33.
16. Moro L, Dolce L, Cabodi S, et al. Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem 2002;277:9405-14.
17. Owens DW, McLean GW, Wyke AW, et al. The catalytic activity of Src family kinases is required to disrupt cadherin-dependent cell-cell contacts. Mol Biol Cell 2000;11:51-64.
18. Fujita Y, Krause G, Scheffner M, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002;4:222-31.
19. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58.
20. Gao Z, Chiao P, Zhang X, et al. Coactivators and corepressors of NF-κB in IκBα gene promoter. J Biol Chem 2005;280:21091-8.
21. Longworth MS, Laimins LA. Histone deacetylase 3 localizes to the plasma membrane and is substrate of Src. Oncogene 2006;25:4495-500.
22. Penuel E, Martin GS. Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways. Mol Biol Cell 1999;10:1693-703.
23. Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinima cells in an orthotopic nude mouse model. Am J Pathol 2006;168:962-72.
24. Slyke PV, Coll ML, Master Z, Kim H, Filmus J, Dumont DJ. Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk. Mol Cell Biol 2005;25:3831-41.
25. Maroni P, Bendinelli P, Matteucci E, Desiderio MA. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-κB. Carcinogenesis 2007;28:267-79.
26. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA. Regulation of DNA methylation in human breast cancer. J Biol Chem 2002;277:41571-9.
27. González L, Agulló-Ortuño MT, García- Martínez JM, et al. Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 2006;281:20851-64.
28. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastasis and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006;318:161-72.
29. Stoica GE, Franke TF, Wellstein A, et al. Estradiol rapidly activates Akt via the ErbB2 signalling pathway. Mol Endocrinol 2003;17:818-30.
30. Mazzone M, Comoglio PM. The Met pathway: master switch and drug target in cancer progression. FASEB J 2006;20:1611-21.
31. Desiderio M.A. Hepatocyte growth factor in invasive growtth of carcinomas. Cell Mol Life Sci 2007;64:1341-54.
32. Perkins ND. The Rel/NF-κB family: friend and foe. Trends Biochem Sci 2000;25:434-40.
33. Helbig G, Christopherson KW II, Bhat-Nakshatri P, et al. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631-8.
34. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7.
35. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncol 2005;7:436-51.
36. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
37. Ducasse M, Brown MA. Epigenetic aberrations and cancer. Mol Cancer 2006;5:60-70.
38. Boyer B, Bourgeois Y, Poupon MF. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 2002;21:2347-56.
39. Myoui A, Mishimura R, Williams PJ, et al. c-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-33.
40. Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin- mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 2002;62:2669-74.
41. Kermorgant S, Zicha D, Parker PJ. Protein kinase C controls microtubule-based traffic but nonproteasomal degradation of c-Met. J Biol Chem 2003;278:28921-9.
42. Rayala SK, den Hollander P, Balasenthil S, et al. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. J Biol Chem 2006;281:4395-403.
43. Yan D, Guo L, Wang Y. Requirement of dendritic Akt degradation by the ubiquitin-proteasome system for neuronal polarity. J Cell Biol 2006;174:415-24.
44. Zeng L, Xiao Q, Margariti A, et al. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. J Cell Biol 2007;174:1059-69.
45. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kB/p65 DNA binding. Mol Cancer Res 2005;3:100-9.
46. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev 2007;8:49-62.
47. Karin M, Cao Y, Greten FR, Li Z-W. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
48. Gort EH, Groot AJ, Derks van de Ven TLP, et al. Hypoxia-inducible factor-1α expression requires PI3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. Oncogene 2006;25:6123-7.
49. Tacchini L, Dansi P, Matteucci E, Desiderio MA. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 2001;22:1363-71.
50. Tacchini L, De Ponti C, Matteucci E, Follis R, Desiderio MA. Hepatocyte growth factor-activated NF-κB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cells. Carcinogenesis 2004;25:2089-100.
51. Lu Y, Yu Q, Lui JH, et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 2003;278:40057-66.
52. Wilson CL, Thomsen J, Hoivik D, et al. Aryl hydrocarbon (Ah) non-responsiveness in estrogen receptor-negative MDA-MB231 cells is associated with expression of a variant Arnt protein. Arch Biochem Biophys 1997;346:65-73.